Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)
Year: 2012
Type: conference-abstract
Source: Cancer Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: alpelisib, PI3Kα inhibitor, PIK3CA mutation, estrogen receptor-positive breast cancer, metastatic breast cancer, HER2-positive breast cancer, PI3K signaling, endocrine therapy resistance, fulvestrant resistance, trastuzumab resistance, lapatinib resistance, maximum tolerated dose, dose-limiting toxicity, advanced solid tumors
Open Access status: closed
OpenAlex ID: W2065481080
